The Week in Review: April 13 – April 20, 2018

Friday, April 20, 2018 News Recap: Green tea supplements may cause liver damage, warns EU watchdog. Green tea extracts may cause liver damage, the EU food safety watchdog today announced. Taking more than 800mg of green tea catechins each day may pose health concerns, according to the body's review. Officials were unable to confirm a safe dose. Race May Affect Ability to Achieve SVR in Hepatitis C.  After being treated with direct-acting antiviral...

Race May Affect Ability to Achieve SVR in Hepatitis C

After being treated with direct-acting antivirals, African Americans with hepatitis C are less likely to achieve sustained virologic response at 12 weeks (SVR12) compared with white patients, according to results published in Pharmacology Research & Perspectives. Patients with hepatitis C who have advanced fibrosis are also less likely to achieve SVR12 than patients who do not have fibrosis. After adjusting for variables, the researchers found that

Alcoholic liver disease replaces hepatitis C infection as the leading cause of liver transplantation in patients without hepatocellular carcinoma in the USA

EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER -- 11 April 2018, Paris, France: Two independent studies have today reported that alcoholic liver disease has now replaced hepatitis C virus (HCV) infection as the leading cause of liver transplantation in the USA in patients without HCC. Non-alcoholic steatohepatitis (NASH) is also on the increase, now ranking second as a cause of liver transplantation due to chronic liver disease. Chronic HCV infection

The Week in Review: March 9 – March 16, 2018

Friday, March 16, 2018 News Recap: Canada: Treatment: Fantastic news from both BC and Quebec this last week:  All restrictions to treatment under the respective provincial PharmaCare plans have been removed!! See Chronic hepatitis C medication now available for all British Columbians, and Quebec Expands Patient Access to Chronic Hepatitis C Therapies. Grants Awarded to 13 Canadian Initiatives to Help Advance the Goal of Eliminating Chronic Hep...

Study shows shorter hepatitis C regimen effective in black patients

Boston, MA - A study by the Harvard Pilgrim Health Care Institute found that contrary to current hepatitis C treatment guidelines, an eight-week treatment regimen may be just as effective as 12 weeks in black patients. The new study of more than 2,600 patients in Kaiser Permanente's Northern California region also showed that more people overall could take advantage of the shorter treatment duration, which has important implications for access given the m

The Week in Review: August 11 – August 18, 2017

Friday, August 18, 2017 Canada Great news in Canada. Two new drug regimens have been approved:  Vosevi from Gilead is a pangenotypic for retreatment of those who have failed previous DAA therapy Gilead Receives Approval in Canada for VOSEVI™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection. And MAVIRET from AbbVie is the first and only 8-week, pan-genotypic treatment for hepatit...

Steatosis: An Independent Risk Factor for Fibrosis in Chronic HCV

Steatosis is an independent risk factor for fibrosis in African-Americans with chronic HCV infection. A study recently published in Digestive Disease Science found that hypertension, older age, obesity, and HIV are risk factors and that steatosis is an independent risk factor for liver fibrosis in African-Americans with chronic hepatitis C. "Our retrospective study showed that there are risk factors, such as HIV coinfection for progression of liver fib

Race does not impact early mortality among patients with chronic HCV

Recent findings published in the Journal of Viral Hepatitis showed that race was a nonfactor in the early mortality of patients with hepatitis C virus infection. African-American patients with kidney disease and low albumin, however, were at greater risk for HCV-related mortality. “All patients with chronic HCV regardless of race died at an earlier age (53-65 years) than predicted for the overall population (75-79 years),” Paul H. Naylor, PhD, assistant p